ABSTRACT
Background: COVID-19 infection can cause an exaggerated immune response. This immune response is associated with an increase in proinflammatory cytokines, especially interleukin-6 (IL-6). High IL-6 levels are found in the acute stage of COVID-19, and IL-6 can induce an excessive humoral inflammatory response. This study aimed to provide an overview of IL-6 levels in coronavirus disease 2019 (COVID-19) patients at Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: Descriptive observational study of 102 research subjects. Observations on sociodemographic, clinical, and laboratory data were carried out in this study. Univariate analysis was carried out using SPSS version 25. Results: Patients with symptom onset <7 days had higher IL-6 levels than those with an onset of more than 7 days. Patients with critical degrees have the highest IL-6 levels compared to moderate and severe degrees. Patients with more than 1 comorbid had higher IL-6 levels than patients who had no comorbid or only had 1 comorbid. Patients with <21 days of treatment had higher IL-6 levels than patients with more than 21 days of treatment. Conclusion: COVID-19 patients at Dr. M. Djamil General Hospital, Padang, Indonesia, with an onset of less than 7 days, a critical degree, and more than 1 comorbidity have higher IL-6 levels.
ABSTRACT
Undoubtedly, vaccination can be one of the promising approaches to control infectious diseases such as the COVID-19 pandemic. Inactivated viral vaccines have a history of "vaccine-induced enhanced disease", which may occur when neutralizing antibodies bind to viral antigens without blocking or clearing the infection. This can cause additional inflammation through the mechanisms described for other respiratory pathogens and lead to acute respiratory distress syndrome. Since the structure and function of SARS-CoV-2 glycoproteins are well known, vaccine manufacturers appear to be careful when inactivating the virus to completely inactivate and maintain the viral epitopes necessary for protective immune induction. It seems that caution should be taken in the usage of inactivated vaccines in children to ensure they are safe and efficacious, vaccinated children should be well monitored and any symptoms should be reported immediately.
ABSTRACT
Toxoplasmosis is a zoonotic illness that spreads from animals to people. Toxoplasma gondii, a protozoan parasite that infects warm-blooded mammals, causes the sickness. Toxoplasmosis is a parasitic infection that causes abortion and death in animals. Cats are the parasite's sole sexual hosts, thus they're the only ones who can get it. Because cats are frequent pets, they are highly likely to come into touch with humans. As a result, the disease poses a risk to human health. The potential danger is influenced by the frequency of oocyst secretion and the level of contamination in the environment. Toxoplasmosis has serious consequences for both animal and human health, hence preventative actions should be taken to reduce the dangers. COVID-19 is affected by such methods as well. Toxoplasmosis is thought to increase immunological and immunosuppressive factors, which increases the chance of SARS-CoV-2 infection and the severity of the resulting COVID-19. Research into Toxoplasma gondii intermediate hosts might help understand COVID-19's dynamics and determine if the virus can be transferred from animals to humans. We explore what we know about Toxoplasma gondii infection as a human parasitosis and how it may alter the course of SARS-CoV-2 infection in this review study.
ABSTRACT
BACKGROUND: Efficacy of COVID vaccines has been evaluated in various studies. The interim analysis from four randomized controlled trials in UK, Brazil, and south Africa regarding efficacy of two doses of the vaccine was found to be 70.4% (95.8% CI 54.8-80.6). There is a limited data on follow-up Ab titer post vaccination. Hence, the current study is first of its kind with the objective to determine vaccine long term efficacy and its determinants. METHODS: Health Care Workers (HCW) from Apollo Multispeciality Hospitals, Kolkata who underwent Covishield vaccination from January 2021 to April 2021 were included in the study. Serological testing was done prior to first and second dose of vaccinations, and additionally around six months post second dose. RESULTS: Between January 2021 to April 2021, 2032 HCW, with predominant age of less than 30 years (44.83%) and male gender (61.96%) undergoing Covishield vaccination were enrolled. Antibodies were detected in 953 (46.9%) individuals prior to first dose, 1449 out of 1495 (96.9%) remained positive prior to second dose and 465 out of 504 (92.3%) HCW after 6 months and remaining 39 (7.7%) either had lost or never had antibodies in their blood. The mean +or- SD value of first, second and third antibodies were 2.35 +or- 3.10, 10.46 +or- 4.84 and 8.75 +or- 4.88 respectively. CONCLUSIONS: This study provides long observation period, covering the complete progress of the pandemic which provides a "real-life" picture of the antibody level dynamics over time, and after vaccination.
ABSTRACT
Objective To investigate the dynamic changes of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific antibody IgG positive rate in coronavirus disease 2019 (COVID-19) survivors in China. Methods the relevant literatures about the positive rate of SARS-COV-2 specific antibody IgG in COVID-19 survivors in China were retrieved from PubMed, Embase, CNKI, Wanfang database and VIP database from December 2019 to February 24, 2022. The quality of the documents were assessed according the revised AHRQ (Agency for Healthcare Research and Quality) statement. Freeman-tukey double arsinusoidal conversion method was used to calculate the positive rate, and StataSE15.0 software was used for statistical analysis. Subgroup analysis was performed according to detection method and fragment, and publication bias was examined by Egger method. Results A total of 12 articles were included, IgG was detected from the first month to the twelfth month after SARS-COV-2 infection, and the total sample size ranged from 74 to 2 907 cases per month. The positive rate was the highest in the second month and the third month, 96.35% (95% CI: 93.98%-98.14%) and 97.23% (95% CI: 94.47%-99.05%) respectively. The positive rate decreased gradually with time, and reached 73.63% (95% CI: 50.31%-91.45%) in the twelfth month. The results of subgroup analysis showed that the heterogeneity between studies with the different detection method and the different detection fragment were significant differences (X2=5.02-39.57, all P < 0.05). Egger method test published bias, and the difference was not statistically significant (t=1.85, P=0.101). Conclusion Most people, one year after infection with SARSCOV- 2, could still detect SARS-COV-2 specific antibody IgG.
ABSTRACT
Introduction: Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome-coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic therapy before coronavirus disease-2019 (COVID-19) for any reason compared to the group who had not. Methods: In this retrospective, multicenter study;patients who were hospitalized between March 11 and July 1, 2020 were divided into two main groups as who had been on anti-thrombotic therapy for any indication use previously at the time of admission or who had not been on anti-thrombotic therapy at the time of admission, and their selected clinical parameters were compared. Results: After analyzing the study population of 124 patients with a homogeneous distribution in terms of age and gender, the comparison of anti-thrombotic users and non-users showed no significant difference in hospitalization. There was a statistically significant decrease in mechanical ventilation apply rate, intensive care unit duration and mortality rate between the group using anti-thrombotic compared to the group not using it (p<0.05). Conclusion: It has already been shown that COVID-19 patients are more prone to thromboembolic events as it activates the coagulation cascade with the cytokine storm it creates and thus the mortality of COVID-19 infection increases significantly. Parallel to this fact the results of our study demonstrated that using anti-thrombotic therapy for any reason may affect the bad prognosis of the disease positively.
ABSTRACT
ObjectiveTo investigate the specific anti-SARS-CoV-2 antibody in adults and above after initial vaccination with inactivated COVID-19 vaccine, and determine the influencing factors. MethodsIn this study, residents aged 18 and above who had completed two doses of inactivated COVID-19 vaccine in Deqing County, Huzhou City, Zhejiang Province were included. Information such as gender, age, type of vaccine and vaccination time were collected, and serum specimens were sampled. Anti-SARS-CoV-2 receptor binding domain (RBD) antibody was quantitatively examined by enzyma-linked immunosorbent assay (ELISA) and influencing factors were determined. ResultsThe median concentration of anti-SARS-CoV-2 IgG antibody in the residents vaccinated with an inactivated booster vaccine was higher than that in those vaccinated with only two doses of COVID-19 vaccine or single dose (P<0.05). The median concentration of IgG antibody in males was 9.73 (4.01-23.70) RUmL-1, lower than 17.76 (7.07-49.23) RUmL-1 in females (P<0.05). The median concentration in the residents vaccinated with BBIBP-CorV (Sinopharm) was 6.53 (0.97-13.69) RUmL-1, which was lower than that in those vaccinated with CoronaVac (Sinovac) that was 17.29 (8.54-43.73) RUmL-1 (P<0.05). The median concentration in those with BBIBP-CorV was also lower than 12 (5.45-40.06) RUmL-1 in those with heterologous booster vaccine (P<0.05). The median concentration was 9.73 (3.83-23.63) RUmL-1 in the residents with an interval of more than 6 months from the second dose, which was lower than 14.66 (6.36-35.98) RUmL-1 in those with an interval of 3-6 months (P<0.05). Moreover, immune effect was better in females (X2=16.464, P<0.05), 18-45 years (X2=7.158, P<0.05), and those vaccinated with CornaVac (X2=49.637, P<0.05), while decreased in those with an interval of more than 6 months from the second dose (X2=8.447, P<0.05). ConclusionGender, age, and type of vaccine may affect the effect of immunization. The COVID-19 vaccination shows an acceptable immunogenicity in adults;however, it declines in 6 months after vaccination. It warrants strengthening the booster vaccination to maintain the immune response.
ABSTRACT
The most significant single nucleotide human leukocyte antigen genes polymorphisms and innate immunity genes associated with varying degrees of acute respiratory infection severity are considered-COVID-19 caused by the SARS-CoV-2 coronavirus. As data accumulated, it became clear that the SARS-CoV-2 virus exhibits significant regional, ethnic, and individual specificity. This is due to the population groups' genetic characteristics. This is necessary to reliably know the human genotype relationship with the COVID-19 course severity (asymptomatic, mild, moderate, severe, and extremely severe up to fatal outcomes) for more successful therapy and vaccination. At the same time, it was also known that the innate immunity system is on the first line of defense against the pathogenic penetration into the body, and the human leukocyte antigen system encodes molecules of the same name on the surface of cells that present various antigens, including viral infection pathogens, and determine the severity of the course of many diseases;therefore, these systems' genes. This approach makes it possible to assess the likelihood of a severe and extremely severe disease course in healthy and infected people, which in turn contributes to the correct therapy strategy, pharmacotherapy, and vaccination, as well as to create new antiviral therapeutic and preventive medicines. The genetically determined immune response heterogeneity to SARS-CoV-2 infection requires further study, since there is no unambiguous opinion about the leading mechanism that determines disease severity.
ABSTRACT
The recent vaccination campaign targeting the new coronavirus infection (COVID-19) carried out in the Armed Forces of the Russian Federation, on the background of the current unstable global pandemic situation, makes it necessary to study post-vaccination population immunity to the SARS-CoV-2 virus and thus identify key features of immunity in organized military collectives. In the future, this will make it possible to objectively assess the risks of a worsening pandemic situation, effectively adjust the ongoing sanitary and anti-epidemic measures aimed at preserving and strengthening the health of military personnel, as one of the main conditions for maintaining the combat readiness of the Armed Forces of the Russian Federation. During a study conducted on epidemic indications, it was found that vaccination with Gam-Covid-Vac contributes to the formation of collective immunity with 95% effectiveness. A gender-based analysis of the immune response showed that the proportion of persons who lack class G immunoglobulins to SARS-CoV-2 among females is twice than that among men (9.3% and 4.7%, respectively). Seroprevalence indicators, classified by blood group, range from 94.4% (AB (IV) Rh-) to 97.4% (A (II) Rh-). There were no significant differences in seroprevalence between groups of people with different blood groups;however, the highest value of seroprevalence was seen among military personnel with blood group A (II) Rh-. In this context, it is advisable to continue monitoring the formation of immunity in individuals with various blood groups. The results obtained made it possible to form a primary medical and social "portrait" of a serviceman with the most adequate immune response to the introduction of the Gam-Covid-Vac vaccine (a man under the age of 20 with blood type A (II) Rh-) and to draw a conclusion about the high effectiveness of vaccination in military units (formations) staffed by conscripts and military educational organizations.
ABSTRACT
Introduction: the daily increase in cases and deaths, the economic losses in the millions suffered by affected nations and the consequent strain on the human resources involved in reversing this situation have made the COVID-19 pandemic an unprecedented international challenge. Background: to describe the orchestrated immune response following SARS-CoV-2 infection. Methods: an up-to-date bibliometric study was conducted on the type of articles stated in the objective, using a total of 30 bibliographies. Documentary review and analysis-synthesis methods were used to prepare the final report. Resources available on the Infomed network were used to select the information, specifically: PubMed and SciELO, through the databases: Medline, Search Premier and Scopus. Development: the core elements in the immunopathology of COVID-19 involve innate immunity, with the sustained increase of pro-inflammatory interleukins associated with failures in the interferon system, which can trigger a potentially fatal cytokine storm. In terms of elements linked to adaptive immunity, there is evidence of marked lymphopenia which, depending on the degree, may indicate the severity of the disease. Conclusions: understanding the orchestrated immune response following SARS-CoV-2 infection and its temporal sequence allows us to choose timely and effective therapies, specifically when selecting anti-inflammatory drugs and the time of their application, as it is difficult to determine when they will be clearly beneficial, that they do not impair the response and that it is not too late, given the irreversibility of the process.
ABSTRACT
The COVID-19 pandemic continues to rage worldwide and the SARS-CoV-2 Omicron variant has now replaced the Delta variant as the leading epidemic strain. Omicron, as one of the SARS-COV-2 variants, incorporates the most critical mutations of the Alpha and Delta variants, and is characterized by having multiple mutation sites, high viral load, stronger infectivity and immune escape, which significantly reduced the protective effect of the vaccine. However, compared with the previous SARS-CoV-2 strains, the Omicron variant is less likely to infect lung tissue, it usually causes mild clinical symptom with reduced hospitalization rate, severe disease rate and fatality rate. Three doses of allogeneic vaccine can offer better tolerance and immunogenicity, and improve the protective effect of the vaccines. The application of small-molecule antiviral drugs and neutralizing antibodies can significantly reduce the hospitalization rate and mortality rate.In this paper, the epidemiological and characteristics of the Omicron variant were reviewed in order to provide reference for clinical diagnosis and treatment of the disease.
ABSTRACT
The relationship between smoking and the lung damage volume in patients with a confirmed new coronavirus infection diagnosis, hospitalized in a temporary infectious hospital for the treatment of patients suffering from a new coronavirus infection and community-acquired pneumonia was evaluated. This was in the Odintsovo District's Patriot Park of the Moscow region. Smoking cigarettes, both active and passive, as well as exposure to tobacco smoke on the body, are important upper and lower respiratory tract infection risk factors due to local immune response suppression. Nevertheless, data from a number of international studies indicate a significantly lower number of hospitalized smoking patients compared to non-smokers. These indicators were investigated as the percentage and degree of lung damage, smoking history, the number of cigarettes smoked per day, and the smoker's index. In the course of the study, the data on a smaller percentage of smokers admitted to inpatient treatment were confirmed in comparison with non-smokers and smokers in the general population. There was no statistically significant difference in the volume of lung damage between smoking and non-smoking patients according to the chest organs computed tomography. At the same time, there was an increase in the volume of lung tissue damage, depending on the smoking experience. This is apparently due to the irreversible changes formation in lung tissue against a long-term smoking background. The median age of smoking patients was 56 years with a variation from 46 to 68 years. The minimum and maximum ages were 29 and 82. The median lung lesion was 32% with a variation from 23% to 39%. The minimum and maximum lung damage is 10% and 40%, respectively. A moderate correlation was found between the smoking experience and the volume of lung damage. An increase in lung damage by 0.309% should be expected with an increase in smoking experience by one full year. There was also no statistically significant difference in the number of cigarettes smoked per day and the smoker's index.
ABSTRACT
The susceptibility of animal species to SARS-CoV-2, under experimental conditions, is a subject of great interest for the international scientific community. Compared to observational studies of natural disease outbreaks in different animal species, experimental studies based on in silico, in vitro and in vivo research, are important alternatives to evaluate the prediction of potential hosts for SARS-CoV-2 infection. In order to determine the susceptibility of a host species and the risk of acting as a potential animal reservoir, a large number of different animal species, domestic and wild, were experimentally infected with SARS-CoV-2, which were classified as permissive or resistant. Experimental infections have proven to be crucial for clarifying aspects of the pathogenetic mechanism, viral persistence and elimination, immune response, antiviral sensitivity, vaccine production, immunotherapy and improving diagnostic methods. In this article, some experimental infections carried out in different animal species will be reviewed, according to the data from the literature.
ABSTRACT
More than 220 countries and territories are globally affected by the recent pandemic COVID-19 which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is possibility of third wave of this pandemic as per epidemiological and public health experts. Besides that post-COVID-19 complications are alarming matter to look upon. Post-COVID-19 complications include several symptoms like as persistent fever;cough;fatigue;headache;attention disorder;dyspnea;anosmia;ageusia;chest pain discomfort;various respiratory illness;acute respiratory distress syndrome (ARDS) etc., and here the things to worry about is the development of pulmonary fibrosis after COVID-19. In some COVID-19 patients, hyper-inflammation in the form of 'cytokine storm' along with dysregulated immune response, alveolar epithelial tissue injury and wound repair collectively cause this secondary pulmonary fibrosis. Therefore, using anti-fibrotic agents e.g. pirfenidone, nintedanib and other natural compounds could be meaningful in these circumstances although their efficacy in treating COVID-19 is subject to more detailed laboratory research works. In this review article, we have discussed the progression of pulmonary fibrosis development which is triggered by COVID-19;probable solutions with anti-fibrotic agents including anti-fibrotic drugs, some well-known natural compounds, combined anti-fibrotic therapies;and the current challenges of this field.
ABSTRACT
Against a pandemic of emerged infectious disease, COVID-19, new generation vaccines based on nucleic acids or recombinant viruses, which had not been used as vaccines in humans, have been inoculated and shown to be successful. They are, however, heat-labile and need a cold-chain including deep-freezers for storage and transportation. Vaccinia virus (VAC) vector vaccine (VACV) is a pioneer of new generation of vaccines constructed by using molecular biological technology. VACV, which has contributed to eradication of smallpox, has excellent characteristics of vaccinia virus such as a high heat-stability and long-lasting immunological effects. It is possible to distinguish the immunological responses of vaccination from those of natural infections. We started our developmental researches 35 years ago, using attenuated VAC strains established in Japan. In this article, we first describe the early researches of VACVs;development of two VACVs for Bovine leukemia virus and Rinderpest morbillivirus antigens and their protective immunity in large mammals, sheep and cows. Second, application of VACV is described;Rabies-VACV, which has already been licensed, used in the field in Europe and USA, and resulted in a prominent decrease of rabies. Then, current status of VACV research is described;non-replicating VACVs in mammalian cells have been developed as new-generation and ultimately-safe vaccines. We discuss the possibility of future application of VACV for wildlife.
ABSTRACT
COVID-19 is a viral respiratory infection caused by SARS-CoV-2. The immune system plays a pivotal role in disease resolution but can also be detrimental to the clinical outcome in case of unbalanced immune activation. In this study, we have focused on the parallel expression of IL-6, a potent pro-inflammatory cytokine, and IL-10, an important regulator of the immune response, in COVID-19 patients. Using bead-based multiplex immunoassay technology we compared the serum levels of IL-6 and IL-10 in 47 COVID-19 patients with mild, moderate, or severe disease. The serum concentrations of both cytokines were significantly elevated in patients with severe COVID-19, and there was a significant positive correlation between IL-6 and IL-10 in the moderate and severe groups (R=0.6;p< 0.001). Our observations support that IL-6 is one of the driving forces for the cytokine release syndrome in COVID-19 while the immunosuppressive properties of IL-10 in severe disease act as a hindrance to viral clearance.
ABSTRACT
COVI D-19 has emerged as the most alarming infection of the present time instigated by the virus SARS-CoV-2. In spite of advanced research technologies, the exact pathophysiology and treatment of the condition still need to be explored. However, SARS-CoV-2 has several structural and functional similarities that resemble SARS-CoV and MERS-CoV which may be beneficial in exploring the possible treatment and diagnostic strategies for SARS-CoV-2. This review discusses the pathogen phenotype, genotype, replication, pathophysiology, elicited immune response and emerging variants of SARSCoV- 2 and their similarities with other similar viruses. SARS-CoV-2 infection is detected by a number of diagnostics techniques, their advantages and limitations are also discussed in detail. The review also focuses on nanotechnology-based easy and fast detection of SARS-CoV-2 infection. Various pathways which might play a vital role during SARS-CoV-2 infection have been elaborately discussed since immune response plays a major role during viral infections.
ABSTRACT
Background: The global threat of COVID-19 outbreak and on the 11 March 2020, WHO acknowledged that the virus would likely spread to all countries across the globe and declared the coronavirus outbreak a pandemic which is the fifth pandemic since 20 century and this has brought human lives to a sudden and complete lockdown and the confirmed cases of this disease and deaths continue to rise in spite of people around the world are taking important actions to mitigate and decrease transmission and save lives. Objectives: To assess the effect of exercise and physical activity on the immunity against COVID-19. Methods: Collected electronic databases including (Medline, EMBASE, Google Scholar, PubMed and Web of Science) were searched without language restrictions to recognize all studies and reports on sports and physical activity related to COVID-19 due to alterations in the immune parameters. Results: Physical activity including sports and exercise induces obvious immune responses in many elements of the immune system whether transient or permanent that had a role in defense reaction against infection like COVID-19. This mediated through the nervous and endocrine systems that play a key role in determining exercise induced immune changes. Massive impact sports have on every aspect of our lives. Conclusions: Mild to moderate sports leads to stimulate an immune system that can subside COVID-19 infection and keep each other safe until this outbreak subsides and life is back to being greater than ever.
ABSTRACT
OBJECTIVE: To investigate the immune antibodies in blood specimens of 95 health care workers vaccinated with inactivated 2019-nCoV vaccines and explore the rules and characteristics of production of antibodies after vaccination. METHODS: From Oct 2020 to Jul 2021, the venous blood specimens were collected from 95 health care workers of the 305 Hospital of PLA after the injection of 2 doses of 2019-nCoV vaccines fo30 days, 65 days, 91 days, 6 months and 9 months. SARS-CoV-2 immunoglobin(Ig) M, IgG and titers of neutralizing antibodies and total antibodies were detected by chemiluminescence immunoassay, the results of antibody tests were dynamically analyzed, the immune durability of the antibody, influencing factors and correlation were determined. RESULTS: Almost all of the subjects produced IgG, neutralizing antibody and total antibody, some subjects retained high level of IgM titer. Smoking could affect the production of total antibody. The subjects of the low body weight group produced higher level of IgG, and there was no significant difference when the weight was over 60 kg. The titers of the four types of antibodies decreased significantly at the following time points, and the positive rates of all the antibodies were less than 50% except for IgG after the vaccination for 9 months. CONCLUSION: Specific IgM and IgG, neutralizing antibody and total antibody can be produced after the 2-doses vaccination of inactivated 2019-nCoV vaccines. But the titers and positive rates of the antibodies decrease with time, which means the protective effects on the body decrease. Therefore, in order to improve the autoimmunity against novel coronavirus, one booster vaccination of an inactivated 2019-nCoV vaccine will be necessary after the 2 doses of vaccination for 6 months.
ABSTRACT
This study aimed to explore the protective mechanism of baicalein against porcine deltacoronavirus (PDCoV) infection. The targets of baicalein were obtained through Pharmamapper, Pubchem, STITCH, TCMSP and Swiss Targer Prediction databases, and the targets of PDCoV infection were obtained according to the proteomics data from our previous study. The targets of baicalein-PDCoV interaction were obtained and analyzed by STRING database and Cytoscape 3.8.2 software to construct a network diagram of "baicalein-PDCoV-targets". The CytoNCA was used to analyze network topology and core network construction. Metascape database was used for GO and KEGG analysis of core network genes. The expression levels of genes in the predicted signaling pathways were detected in vitro. A total of 268 potential targets of baicalein were screened out. There were 75 potential targets of baicalein-PDCoV infection. GO enrichment results showed that baicalein was mainly involved in the formations of membrane raft, spindle and mitochondrial membrane, cell cycle and MAPK signaling pathways. A total of 277 signaling pathways (P < 0.01) were screened out by KEGG enrichment. The PI3K-Akt, Ras and MAPK signaling pathways were the main pathways that involved in the protective effects of baicalein against PDCoV infection. The results showed that compared with the cellular control groups, the mRNA expressions of PI3K, AKT and NF-B significantly increased in the PDCoV infection group. Compared with the PDCoV group, treatment of baicalein significantly decreased the mRNA expressions of PI3K, AKT and NF-B (P < 0.05). The effect of baicalein on PDCoV infection has the characteristics of multi-targets and multi-pathways, through the intervention of AKT1, HSP90AA1, SRC, EGFR, CASP3, MAPK, STAT3 and other core genes in regulating PI3K-Akt signaling pathway, Ras signaling pathway and MAPK signaling pathway, apoptosis, and virus infection. These results suggested that baicalein could be a potential therapeutic drug against PDCoV infection for further study.